Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2020

June 2020 | 152 pages | ID: AAF6ADBC63DEN
Global Markets Direct

Abstracts

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease - Pipeline Review, H1 2020, provides an overview of the Anemia in Chronic Kidney Disease (Hematological Disorders) pipeline landscape.
Renal anemia is a disease in which the patient has an unusually low count of red blood cells. Renal is a term that means of the kidneys, so anemia is often associated with kidney disease. This type of anemia is caused by a lack of erythropoietin, a protein produced in the kidneys that helps to create red blood cells. Symptoms caused by renal anemia include pale skin and gums, become short of breath, dizziness and inability to think clearly.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anemia in Chronic Kidney Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Anemia in Chronic Kidney Disease (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Anemia in Chronic Kidney Disease (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Anemia in Chronic Kidney Disease (Renal Anemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 8, 8, 4, 6, 6 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Anemia in Chronic Kidney Disease (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Anemia in Chronic Kidney Disease (Hematological Disorders).
• The pipeline guide reviews pipeline therapeutics for Anemia in Chronic Kidney Disease (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Anemia in Chronic Kidney Disease (Hematological Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Anemia in Chronic Kidney Disease (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Anemia in Chronic Kidney Disease (Hematological Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Anemia in Chronic Kidney Disease (Hematological Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Anemia in Chronic Kidney Disease (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Anemia in Chronic Kidney Disease (Renal Anemia) - Overview
Anemia in Chronic Kidney Disease (Renal Anemia) - Therapeutics Development
Anemia in Chronic Kidney Disease (Renal Anemia) - Therapeutics Assessment
Anemia in Chronic Kidney Disease (Renal Anemia) - Companies Involved in Therapeutics Development
Anemia in Chronic Kidney Disease (Renal Anemia) - Drug Profiles
Anemia in Chronic Kidney Disease (Renal Anemia) - Dormant Projects
Anemia in Chronic Kidney Disease (Renal Anemia) - Discontinued Products
Anemia in Chronic Kidney Disease (Renal Anemia) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by 3SBio Inc, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Akebia Therapeutics Inc, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Amgen Inc, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Apotex Inc, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Bayer AG, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Biocad, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Cadila Healthcare Ltd, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by FibroGen Inc, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by FortuneRock (China) Ltd, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Genexine Inc, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by GlaxoSmithKline Plc, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Great Bay Bio, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by HEC Pharm Co Ltd, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by HK inno.N Corp, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Japan Tobacco Inc, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Liminal BioSciences Inc, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Panacea Biotec Ltd, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Pangen Biotech Inc, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by PharmaEssentia Corp, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by PhytoHealth Corp, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by SunBio Inc, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by UBI Pharma Inc, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Xenetic Biosciences Inc, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Zosano Pharma Corp, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Dormant Projects, H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Dormant Projects, H1 2020 (Contd..1), H1 2020
Anemia in Chronic Kidney Disease (Renal Anemia) - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

3SBio Inc
Akebia Therapeutics Inc
Amgen Inc
Apotex Inc
Bayer AG
Biocad
Cadila Healthcare Ltd
Chong Kun Dang Pharmaceutical Corp
Dong-A Socio Holdings Co Ltd
FibroGen Inc
FortuneRock (China) Ltd
Genexine Inc
GlaxoSmithKline Plc
Great Bay Bio
HEC Pharm Co Ltd
HK inno.N Corp
Japan Tobacco Inc
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Liminal BioSciences Inc
Panacea Biotec Ltd
Pangen Biotech Inc
PharmaEssentia Corp
PhytoHealth Corp
SunBio Inc
Taisho Pharmaceutical Holdings Co Ltd
UBI Pharma Inc
Xenetic Biosciences Inc
Zosano Pharma Corp